PLX2853 to the existing line of care for patients aged 16 and above who are experiencing debilitating symptoms of MF. The goal of PROMise is to find a manageable dose of PLX2853 when used in conjunction with ruxolitinib; evaluate the effectiveness of the combination of PLX2853 and ruxolitinib for the treatment of MF symptoms; evaluate the safety of combining PLX2853 with ruxolitinib.
PROMise will enroll around 60 patients and will be available at 15 NHS locations throughout the UK. TAP is in charge of PROMise, which is sponsored by The University of Birmingham. Financial support and free of cost experimental product PLX2853 will be provided by Plexxicon and trial funding will be provided by CRUK.
Adam Mead, Chief Investigator, Professor of Haematology at University of Oxford explained about the new treatment and thanked Cure Leukaemia for their fund support. He said, “The PROMise study is a really exciting study that has just opened in the UK and will be opening across 15 centres. This is introducing a new treatment called PLX2853, in combination with ruxolitinib, for patients with MF. The impact on patients for this combination of treatments, I hope, will be improvement of their symptoms, improvement of their quality of life, without causing them side effects.” He added, “The funding from Cure Leukaemia is really important for the day-to-day running of this study as Cure Leukaemia are providing nursing support in each of the centres.”
James McLaughlin, CEO of Cure Leukaemia, expressed hopes about the new treatment and also appreciated the fundraising efforts of Cure Leukaemia. He said, “It is fitting to announce this news on World Blood Cancer Day as PROMise is another example of a pioneering blood cancer clinical trial that is now running in the UK thanks to TAP”. He added, “Without Cure Leukaemia’s funds, this study would not be currently recruiting patients and giving them access to potentially life-changing treatment. This highlights why this network is so vital and why funds raised for Cure Leukaemia make a direct impact on the lives of the 38,000 people diagnosed with a form of blood cancer in the UK each year.”
